Literature DB >> 11807176

Drug efficacy at G protein-coupled receptors.

Terry Kenakin1.   

Abstract

Efficacy has been defined in receptor pharmacology as a proportionality factor denoting the amount of physiological response a given ligand imparts to a biological system for a given amount of receptor occupancy. While first defined in terms of response, the concept can be expanded to a wide variety of G protein-coupled receptor (GPCR) behaviors, which includes pleiotropic interaction with multiple G proteins, internalization, oligomerization, desensitization, and interaction with membrane auxilliary proteins. Thus, there can be numerous types of efficacy, and different ligands can have a range of efficacies for different receptor behaviors. This review discusses the use of the efficacy concept in GPCR models based on the thermodynamic linkage theory and also in terms of the protein ensemble theory, in which macroaffinity of ligands for an ensemble of receptor microstates produces a new ligand-bound ensemble. The pharmacological characteristics of the ligand emerge from the intersection of the ligand-bound ensemble with the various ensembles defining pharmacological receptor behaviors. Receptor behaviors discussed are activation of G proteins; ability to be phosphorylated, desensitized, and internalized; formation of dimers and oligomers; and the interaction with auxiliary membrane and cytosolic proteins. The concepts of ligand-specific receptor conformation and conditional efficacy are also discussed in the context of ligand control of physiological response.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11807176     DOI: 10.1146/annurev.pharmtox.42.091401.113012

Source DB:  PubMed          Journal:  Annu Rev Pharmacol Toxicol        ISSN: 0362-1642            Impact factor:   13.820


  96 in total

1.  Astrocyte and glutamate markers in the superficial, deep, and white matter layers of the anterior cingulate gyrus in schizophrenia.

Authors:  Pavel Katsel; William Byne; Panos Roussos; Weilun Tan; Larry Siever; Vahram Haroutunian
Journal:  Neuropsychopharmacology       Date:  2011-01-26       Impact factor: 7.853

Review 2.  Is there a SERT-ain association with IBS?

Authors:  M Camilleri
Journal:  Gut       Date:  2004-10       Impact factor: 23.059

3.  A signal transduction pathway model prototype I: From agonist to cellular endpoint.

Authors:  Thomas J Lukas
Journal:  Biophys J       Date:  2004-09       Impact factor: 4.033

Review 4.  Beyond desensitization: physiological relevance of arrestin-dependent signaling.

Authors:  Louis M Luttrell; Diane Gesty-Palmer
Journal:  Pharmacol Rev       Date:  2010-04-28       Impact factor: 25.468

Review 5.  Seven transmembrane receptors as shapeshifting proteins: the impact of allosteric modulation and functional selectivity on new drug discovery.

Authors:  Terry Kenakin; Laurence J Miller
Journal:  Pharmacol Rev       Date:  2010-04-14       Impact factor: 25.468

6.  Ligand-induced internalization and recycling of the human neuropeptide Y2 receptor is regulated by its carboxyl-terminal tail.

Authors:  Cornelia Walther; Stefanie Nagel; Luis E Gimenez; Karin Mörl; Vsevolod V Gurevich; Annette G Beck-Sickinger
Journal:  J Biol Chem       Date:  2010-10-18       Impact factor: 5.157

Review 7.  The mass action equation in pharmacology.

Authors:  Terry Kenakin
Journal:  Br J Clin Pharmacol       Date:  2015-12-21       Impact factor: 4.335

8.  Distinct profiles of functional discrimination among G proteins determine the actions of G protein-coupled receptors.

Authors:  Ikuo Masuho; Olga Ostrovskaya; Grant M Kramer; Christopher D Jones; Keqiang Xie; Kirill A Martemyanov
Journal:  Sci Signal       Date:  2015-12-01       Impact factor: 8.192

9.  A new ligand for the urotensin II receptor.

Authors:  Valeria Camarda; Remo Guerrini; Evi Kostenis; Anna Rizzi; Girolamo Calò; Almut Hattenberger; Marina Zucchini; Severo Salvadori; Domenico Regoli
Journal:  Br J Pharmacol       Date:  2002-10       Impact factor: 8.739

10.  Pharmacological profile of the cyclic nociceptin/orphanin FQ analogues c[Cys10,14]N/OFQ(1-14)NH2 and c[Nphe1,Cys10,14]N/OFQ(1-14)NH2.

Authors:  M Kitayama; T A Barnes; G Carra; J McDonald; G Calo; R Guerrini; D J Rowbotham; G Smith; D G Lambert
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-11-04       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.